Serina Therapeutics, Inc.

Serina is a clinical-stage biotechnology company that develops polymer-based drug therapies for neurological disorders and other conditions. The company utilizes a proprietary poly(2-oxazoline) polymer delivery platform to attach and release therapeutics, such as small molecules, antibody-drug conjugates, and lipid nanoparticles for ribonucleic acid vaccines. Its drug development pipeline includes SER-252, an injectable dopamine agonist conjugate under clinical investigation for advanced Parkinson’s disease, and SER-214 for early-stage disease. Serina targets patients requiring sustained drug release and collaborates with biopharmaceutical companies seeking polymer technologies for drug delivery applications.

The company operates at the clinical stage, having dosed patients in a Phase 1b clinical trial and completed an earlier Phase 1a study with 19 participants. Its development scale includes preclinical evaluations in animal models and research partnerships with pharmaceutical companies, including a non-exclusive licensing agreement with Pfizer. The text notes regulatory and clinical references in the United States, Europe, and Scotland. Serina does not disclose its corporate headquarters, facility locations, or total employee headcount in the text.

Summary of the business section of Serina Therapeutics's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of December 31, 2025, we had 16 full time employees and, in connection with the growth and advancement of our pipeline, we expect to increase the number of our employees and the scope of our operations, particularly in the areas of product development, business development, regulatory affairs, and sales and marketing.”